Elevance Health, Inc. (ELV)

Elevance Health, Inc.'s Q·Score is 5.9/10 (Neutral), reflecting its current fundamentals, analyst data, and valuation metrics. 68% of 22 covering analysts have a positive rating. Key area to monitor: earnings contracting 17% year-over-year. This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.

The consensus price target for ELV is $404.05, based on ratings from 21 Wall Street analysts. This is 3.2% above the current price of $391.47. Price targets are forward-looking estimates and not guarantees of future performance.

Elevance Health, Inc. (ELV) scores in line with sector averages on valuation metrics. Its forward P/E ratio stands at 13.4×.

Elevance Health, Inc.'s next earnings report is expected on approximately July 16, 2026.

Elevance Health, Inc. has a net profit margin of 2.6%, which is positive but relatively thin. Its gross margin stands at 25.9%, reflecting a more cost-intensive business model.

Elevance Health, Inc. currently offers a dividend yield of 1.76%, a modest payout typical for growth-oriented companies. Dividend yields can change based on price movements and company payout decisions.

Elevance Health, Inc. is reporting modest revenue growth of 2.6%. However, earnings declined 16.8%, which warrants monitoring.

Elevance Health, Inc. has a debt-to-equity ratio of 0.72×, reflecting a moderate debt level, which is manageable for most profitable companies. Its current ratio is 1.48×, suggesting it should be monitored for near-term liquidity.